Climbing a new path allows chemists to ascend cancer’s steepest research challengesThe cancer gene MYC drives unrestrained cancer cell growth, but has proved a difficult drug target. Nature-inspired compounds succeed by chopping up MYC’s RNA.A collab
The "Mount Everest" of cancer genes, MYC, has been targeted by a new RNA degrader approach, where cellular recycling enzymes are directed to cancer gene RNA to remove key segments.